Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline InsightsDelveInsight, the leading market research and consulting company has added a new report “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015” to its portfolio.
By: DelveInsight Business Research · 70+ pipeline drugs with 19+ companies actively involved in drug development. There are 2 drugs in phase III, 1 in phase II/III, 9 in phase II, 4 in phase I/II, 8 in phase I, 31 in pre-clinical, 12 in discovery, 3 in inactive and 4 in discontinued. · Alnylam Pharmaceuticals is developing a lead product ALN-TTR02 which is in Phase III. · R&D activities and technologies used along with the pipeline molecules in development. · Therapeutic assessments by molecule types, route of administration, monotherapy and combination products. · Information related to collaborations, in-licensing and out-licensing deals. DelveInsights, Small interfering RNA (siRNA) Therapeutics- DelveInsight is offering the Report at a price of USD 2250 as a single user license, USD 4500 as a site license and USD 6500 as a Global/Enterprise License. For more information on Small interfering RNA (siRNA) Therapeutics- Contact Us: DelveInsight Business Research New Delhi-110075, India Phone: +91-11-45689769, +91 9650213330 Website: http://delveinsight.com About Us DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|